I urge my colleagues to take swift action and aggressive action because we do not have a moment to waste.

The cost of developing a drug has doubled, as has the number of clinical trials necessary to file a new drug application.

We have a huge opportunity to incentivize them.

the cost of developing a drug has doubled, as has the number of clinical trials necessary to file a new drug application.

To help close this innovation gap, as part of 21st Century Cures Initiative, we must take a fresh look at the challenges facing innovative companies and make certain the right incentives are in place so America is home to the next…

We must take a fresh look at the challenges facing innovative companies and make certain the right incentives are in place.

I am particularly interested in better understanding what we can do to make it more attractive for companies and venture capitalists to invest.

Today's hearing provides us with an opportunity to examine an important aspect of the 21st Century Cures Initiative.

Representative McKinley has authored H.R. 4673, a bill that would combine the various post-acute care payments into one reimbursement payment or bundle.

I and Ranking Member Pallone felt it important for the members of this subcommittee to hear the pros and cons of potential policies in this space.

Today's hearing is designed to educate members on a topic that has come up repeatedly in recent years: site-neutral payments.

Representatives Mike Rogers and Doris Matsui introduced H.R. 2869, a proposal that would require Medicare to pay for cancer services at the same rate regardless of the site of service.